Thoughts on Healthcare Markets and Technology

Thoughts on Healthcare Markets & Technology Podcast

Expert analysis of healthcare & life sciences markets, investment, policy, entrepreneurship, technology and AI — for investors, entrepreneurs, executives, and physicians navigating the business of healthcare and life sciences. www.onhealthcare.tech

Author

Thoughts on Healthcare Markets and Technology

Category

Technology

Podcast website

www.onhealthcare.tech

Latest episode

Jul 10, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 5M+ downloads · 4.8 rating iOS soon

Episodes

Part I: How Geotagged EVV Check-In Data Can Get Wired Into Medicaid and Medicare Managed Care Claim Edits to Reject Home Health Fraud at Submission and Break the Decade-Long Federal Moratorium Loop 15.05.2026

CMS just reimposed a nationwide home health agency moratorium. LA County has 12-15% of all HHAs while holding 3% of Medicare beneficiaries. Ohio found 18 agencies at one address. The pay-and-chase loop is running again. Here is the absurd part. GPS-verified visit data is already being collected at every Medicaid home health visit under the 21st Century Cures Act mandate. Six data elements, includi...

Part I: Why The Q1 2026 Payer Margin Rebound At UnitedHealth, CVS, Elevance, Humana, Centene & Molina Is Really A Benefit Design Recession Built On Repricing, Product Exits, & Tighter Utilization Mgmt 13.05.2026

Q1 2026 managed care earnings looked like a recovery. They were not. Here is what actually happened across UHC, CVS, Elevance, Humana, Centene, and Molina. Cost trend did not reverse. Hospital costs are still up. Senior utilization is still elevated. Specialty drug spend is still ugly. Plans just stopped waiting for the trend to fix itself. What changed: benefit design tightened, networks narrowed...

Part I: What the Six Hundred Billion Dollar MFN Headline Misses: The Best Price Carveout, the IQVIA Net Price Hole, and the CMMI BALANCE Workaround That Makes Trump’s Drug Pricing Framework Run 11.05.2026

The CEA’s six hundred billion dollars drug savings projection is built on data the report’s own footnotes say don’t measure net prices. The policy is net-price-based. The data are gross-price-based. Why did seventeen pharma CEOs sign voluntary MFN deals without anyone forcing them? One sentence in CMS guidance: GENEROUS supplemental rebates won’t affect Medicaid Best Price or three hundred forty b...

Part I: What the Smart Money Just Bought in Healthcare and Life Sciences VC Over the Last Sixty Days 09.05.2026

$2.58B across 10 healthcare VC rounds in 60 days. The pattern is clear: capital is concentrating on scarce inputs, not apps. Sanofi is writing equity into Earendil after a $2.56B deal. Regeneron put $200M into TriNetX for exclusive multi-omic data rights. Pharma is not renting access anymore. It is buying it. Earendil at $787M. WHOOP at $575M with Abbott and Mayo on the cap table. Beeline at $300M...

Part I: The OpenAI Anthropic Arms Race Pivoted From Models To Services & Deployment. And Why Healthcare Is The Stress Test. 06.05.2026

Quick Links: Knowledge Base, Podcast, and Social Knowledge Base — search and filter every article and podcast episode by topic, section, and keyword: kb.onhealthcare.tech Listen to the Podcast — every article is also available as an audio episode. Free subscribers get the public episodes; paid subscribers get the full archive including subscriber-only episodes. Listen on Apple Podcasts , Spotify ,...

Part I: What the Harvard ER Study Says About o1 Beating Doctors at Diagnosis, Why It Means Differential Diagnosis Just Stopped Being a Scarce Cognitive Asset, and Where the Money Goes Next 05.05.2026

Quick Links: Knowledge Base, Podcast, and Social Knowledge Base — search and filter every article and podcast episode by topic, section, and keyword: kb.onhealthcare.tech Listen to the Podcast — every article is also available as an audio episode. Free subscribers get the public episodes; paid subscribers get the full archive including subscriber-only episodes. Listen on Apple Podcasts , Spotify ,...

Part I: FDA Closes the 503B Bulks Door on Semaglutide, Tirzepatide, and Liraglutide: How the April 30 Proposal Kills the Compounded GLP-1 Supply Chain and Draws a Hard Line Between Clinical Need and Economic Need 04.05.2026

Quick Links: Knowledge Base, Podcast, and Social Knowledge Base — search and filter every article and podcast episode by topic, section, and keyword: kb.onhealthcare.tech Listen to the Podcast — every article is also available as an audio episode. Free subscribers get the public episodes; paid subscribers get the full archive including subscriber-only episodes. Listen on Apple Podcasts , Spotify ,...

Part I: The Preclinical Signal in Routine Abdominal CT: How Mayo's REDMOD and the Pre-Diagnostic Pancreas Force a Rethink of Cancer Screening Math, Workflow Economics, and the Multimodal Future of Risk Inference 04.05.2026

Quick Links: Knowledge Base, Podcast, and Social Knowledge Base — search and filter every article and podcast episode by topic, section, and keyword: kb.onhealthcare.tech Listen to the Podcast — every article is also available as an audio episode. Free subscribers get the public episodes; paid subscribers get the full archive including subscriber-only episodes. Listen on Apple Podcasts , Spotify ,...

The FDA Real Time Clinical Trial Announcement Quietly Dissolves Phase Gates, Breaks Biotech Capital Markets Plumbing, and Opens a Founder Sized Hole in Trial Infrastructure, Financing, and Workflow 30.04.2026

Thoughts on Healthcare Markets & Technology is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Welcome to Healthcare Markets & Technology. Rigorous analysis of AI, policy, capital, technology, and clinical operations across U.S. healthcare — written for the people who build, invest in, and lead it. Free subscribers get 2 public...

How AI, Value Based Care Bundles, Medicare Payment Compression, and IMG-Driven Residency Match Dynamics Will Reshuffle the Wealthiest Physician Specialty Rankings Over the Next Five to Ten Years 28.04.2026

Thoughts on Healthcare Markets & Technology is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Welcome to Healthcare Markets & Technology. Rigorous analysis of AI, policy, capital, technology, and clinical operations across U.S. healthcare — written for the people who build, invest in, and lead it. Free subscribers get 2 public...

When $Hims Lost Its Moat 28.04.2026

This is a free preview of a paid episode. To hear more, visit www.onhealthcare.tech In this episode, we walk through the public filings and regulatory sequence that restructured Hims's entire GLP-1 economics between February and April 2026. You'll learn exactly what the Novo settlement and LillyDirect routing arrangement actually mean for margin structure, why the bear case and bull case are simul...

Decoding the CMS Access Model: Half Your Revenue Lives in Escrow 25.04.2026

In this episode, we explore the CMS ACCESS model—a fundamentally new payment infrastructure that withholds fifty percent of chronic care revenue and releases it only if you hit clinical outcome thresholds. We break down why this model is an existential threat to single-condition point solutions, a working capital crisis for undercapitalized companies, and a strategic advantage for integrated platf...

What does 17 pharma MFN deals are underneath the press releases: the real primary source stack, the GLP1 numbers, TrumpRX plumbing, and where the new adjudication layer gets monetized 25.04.2026

Thoughts on Healthcare Markets & Technology is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Welcome to Healthcare Markets & Technology. Rigorous analysis of AI, policy, capital, technology, and clinical operations across U.S. healthcare — written for the people who build, invest in, and lead it. Free subscribers get 2 public...

The BALANCE Model Pause, the GLP-1 Bridge Extension Thru Dec 2027 & What the 80% Part D Participation Threshold Miss Signals About Medicare’s First Real Attempt to Negotiate Anti-Obesity Drug Coverage 23.04.2026

Thoughts on Healthcare Markets & Technology is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Welcome to Healthcare Markets & Technology. Rigorous analysis of AI, policy, capital, technology, and clinical operations across U.S. healthcare — written for the people who build, invest in, and lead it. Free subscribers get 2 public...

Start Here: How to Get the Most Out of This Newsletter 23.04.2026

Welcome to Healthcare Markets and Technology. This episode introduces the newsletter — covering business, policy, and technology forces reshaping the US healthcare system for investors, operators, and entrepreneurs who need to stay ahead of the curve. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.onhealthcare.tech/subscrib...

The Prior Auth API Economy: How CMS-0057-F, CMS-0062-P, Da Vinci FHIR Rails, State Gold Carding Laws, AI Guardrails, and the AHIP/BCBSA 257M Commitment Turn UM Into a Programmable Transaction 22.04.2026

Thoughts on Healthcare Markets & Technology is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Welcome to Healthcare Markets & Technology. Rigorous analysis of AI, policy, capital, technology, and clinical operations across U.S. healthcare — written for the people who build, invest in, and lead it. Free subscribers get 2 public...

The AI Drug Discovery Capital Stack in 2026: Who Has Raised the Most, Why Their Technical Approaches Actually Differ, and Which Recent Industry and Academic Papers Are Worth a Real Read 21.04.2026

Thoughts on Healthcare Markets & Technology is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Welcome to Healthcare Markets & Technology. Rigorous analysis of AI, policy, capital, technology, and clinical operations across U.S. healthcare — written for the people who build, invest in, and lead it. Free subscribers get 2 public...

How Late 2025 and Early 2026 Earnings Calls Expose the Medicare Advantage Pullback, the Migration of Margin From Insurance to Services, and the Quiet Redistribution of Healthcare Profit Pools 20.04.2026

Thoughts on Healthcare Markets & Technology is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Welcome to Healthcare Markets & Technology. Rigorous analysis of AI, policy, capital, technology, and clinical operations across U.S. healthcare — written for the people who build, invest in, and lead it. Free subscribers get 2 public...

The CMS national provider directory: a complete analysis of 27.2 million healthcare records in the entrepreneurial opportunity that they represent 18.04.2026

Thoughts on Healthcare Markets & Technology is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Welcome to Healthcare Markets & Technology. Rigorous analysis of AI, policy, capital, technology, and clinical operations across U.S. healthcare — written for the people who build, invest in, and lead it. Free subscribers get 2 public...

Goodfire AI and the Billion Dollar Bet on Neural Network Interpretability: Why Reverse Engineering Foundation Models Matters for Health Tech Investors Watching the Life Sciences AI Stack Take Shape 17.04.2026

Thoughts on Healthcare Markets & Technology is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Welcome to Healthcare Markets & Technology. Rigorous analysis of AI, policy, capital, technology, and clinical operations across U.S. healthcare — written for the people who build, invest in, and lead it. Free subscribers get 2 public...

The Category 2 Peptide Unwind: How a Rogan Appearance, 14 Withdrawn Nominations & a July PCAC Docket Will Reprice the Compounding Pharmacy Stack, GLP-1 Gray Market, and Longevity Clinic Supply Chain 16.04.2026

Thoughts on Healthcare Markets & Technology is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Welcome to Healthcare Markets & Technology. Rigorous analysis of AI, policy, capital, technology, and clinical operations across U.S. healthcare — written for the people who build, invest in, and lead it. Free subscribers get 2 public...

The FDA Just Rewrote the Rules for Gene Therapy Approval & Most Investors Haven’t Noticed Yet: The Plausible Mechanism Framework and NGS Safety Guidance That Could Reshape Rare Disease Investment 15.04.2026

Thoughts on Healthcare Markets & Technology is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Welcome to Healthcare Markets & Technology. Rigorous analysis of AI, policy, capital, technology, and clinical operations across U.S. healthcare — written for the people who build, invest in, and lead it. Free subscribers get 2 public...

Listen to the Thoughts on Healthcare Markets & Technology Podcast podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.